According to Renub Research Treatment-Resistant Depression (TRD) Market is expected to grow steadily from USD 3.12 billion in 2024 to USD 5.58 billion by 2033, registering a CAGR of 6.67% over the forecast period. Market expansion is fueled by the rising global burden of major depressive disorder (MDD), greater awareness of mental health treatment options, and growing adoption of next-generation therapies such as ketamine, esketamine, psychedelic-assisted treatments, and neuromodulation technologies.
As the global healthcare industry prioritizes psychiatric care and personalized medicine, the TRD market is witnessing accelerated innovation, cross-sector collaboration, and increased investment in breakthrough therapeutic modalities. Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=treatment-resistant-depression-mark…Treatment-Resistant Depression Market: Drug Classes and End-User Trends 2025–33
Treatment Resistant Depression Market Size, Trends & Forecast (2025–2033)
Read more